NASDAQ: SILKSilk Road Medical Inc Stock
$17.65+0.08 (+0.46%)
Updated Apr 25, 2024
SILK Price
$17.65
Fair Value Price
N/A
Market Cap
$691.43M
52 Week Low
$6.08
52 Week High
$45.09
P/E
-12.26x
P/B
4.57x
P/S
2.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$177.13M
Earnings
-$55.74M
Gross Margin
71.7%
Operating Margin
-27.59%
Profit Margin
-31.5%
Debt to Equity
0.76
Operating Cash Flow
-$32M
Beta
1.27
Next Earnings
Jun 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SILK Overview
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SILK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SILK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SILK is poor value based on its book value relative to its share price (4.57x), compared to the US Medical Devices industry average (3.71x)
P/B vs Industry Valuation
SILK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SILK due diligence checks available for Premium users.
Be the first to know about important SILK news, forecast changes, insider trades & much more!
SILK News
Valuation
SILK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.26x
Industry
29.73x
Market
40.97x
SILK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.57x
Industry
3.71x
SILK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SILK's financial health
Profit margin
Revenue
$47.3M
Net Income
-$12.9M
Profit Margin
-27.3%
SILK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SILK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$265.3M
Liabilities
$114.2M
Debt to equity
0.76
SILK's short-term assets ($240.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SILK's short-term assets ($240.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SILK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SILK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.5M
Investing
-$1.6M
Financing
$1.1M
SILK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SILK vs Medical Device Stocks
Silk Road Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.